Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus SPRX 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus SPRX 3.
REDEMPLO vs SPRX-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
Selective sigma-2 receptor ligand; induces mitochondrial dysfunction and endoplasmic reticulum stress leading to apoptosis in cancer cells. Also modulates autophagy.
100 mg orally once daily, with or without food.
Not established; investigational drug. No approved standard adult dose available.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Terminal elimination half-life: 12 ± 3 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Primarily renal (70% unchanged, 15% as glucuronide conjugate); biliary/fecal (10%); other (5%).
Category C
Category C
Unknown
Unknown